By
Drug Target Review2024-01-22T12:00:21
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T11:12:00Z
2026-05-05T13:24:00
Sponsored by HUB Organoids
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2023-01-10T09:50:16
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2026-07-10T06:15:00
Contributor Professor Donald E Ingber, By Drug Target Review
2023-03-03T14:06:14
Sponsored by Bio-Techne
Site powered by Webvision Cloud